Literature DB >> 26855282

HT-SPOTi: A Rapid Drug Susceptibility Test (DST) to Evaluate Antibiotic Resistance Profiles and Novel Chemicals for Anti-Infective Drug Discovery.

Cynthia A Danquah1,2,3, Arundhati Maitra1,3, Simon Gibbons2, Jane Faull1, Sanjib Bhakta1.   

Abstract

Antibiotic resistance is one of the major threats to global health and well-being. The past decade has seen an alarming rise in the evolution and spread of drug-resistant strains of pathogenic microbes. The emergence of extensively drug resistant (XDR) strains of Mycobacterium tuberculosis and antimicrobial resistance among the ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species) as well as fungal pathogens (such as certain species of Candida, Aspergillus, Cryptococcus, and Trichophyton) poses a significant 21st century scientific challenge. With an extremely limited arsenal of efficacious antibiotics, techniques that can (a) identify novel antimicrobials and (b) detect antimicrobial resistance are becoming increasingly important. In this article, we illustrate the HT-SPOTi, an assay that is principally based on the growth of an organism on agar medium containing a range of different concentrations of drugs or inhibitors. The simple methodology makes this assay ideal for evaluating novel antimicrobial compounds as well as profiling an organism's antibiotic resistance profile.
Copyright © 2016 John Wiley & Sons, Inc.

Entities:  

Keywords:  HT-SPOTi; antimicrobial resistance; diagnosis; drug discovery; drug susceptibility testing (DST); infectious diseases; whole-cell phenotypic evaluation

Mesh:

Substances:

Year:  2016        PMID: 26855282     DOI: 10.1002/9780471729259.mc1708s40

Source DB:  PubMed          Journal:  Curr Protoc Microbiol        ISSN: 1934-8525


  13 in total

1.  Early diagnosis and effective treatment regimens are the keys to tackle antimicrobial resistance in tuberculosis (TB): A report from Euroscicon's international TB Summit 2016.

Authors:  Arundhati Maitra; Tengku Karmila Kamil; Monisha Shaik; Cynthia Amaning Danquah; Alina Chrzastek; Sanjib Bhakta
Journal:  Virulence       Date:  2016-11-04       Impact factor: 5.882

2.  DNA sequence-selective C8-linked pyrrolobenzodiazepine-heterocyclic polyamide conjugates show anti-tubercular-specific activities.

Authors:  Federico Brucoli; Juan D Guzman; Mohammad A Basher; Dimitrios Evangelopoulos; Eleanor McMahon; Tulika Munshi; Timothy D McHugh; Keith R Fox; Sanjib Bhakta
Journal:  J Antibiot (Tokyo)       Date:  2016-05-11       Impact factor: 2.649

Review 3.  Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs.

Authors:  Arundhati Maitra; Sadé Bates; Monisha Shaik; Dimitrios Evangelopoulos; Ibrahim Abubakar; Timothy D McHugh; Marc Lipman; Sanjib Bhakta
Journal:  Br Med Bull       Date:  2016-05-05       Impact factor: 4.291

Review 4.  Host Antimicrobial Peptides: The Promise of New Treatment Strategies against Tuberculosis.

Authors:  Javier Arranz-Trullén; Lu Lu; David Pulido; Sanjib Bhakta; Ester Boix
Journal:  Front Immunol       Date:  2017-11-07       Impact factor: 7.561

5.  Human Antimicrobial RNases Inhibit Intracellular Bacterial Growth and Induce Autophagy in Mycobacteria-Infected Macrophages.

Authors:  Lu Lu; Javier Arranz-Trullén; Guillem Prats-Ejarque; David Pulido; Sanjib Bhakta; Ester Boix
Journal:  Front Immunol       Date:  2019-07-02       Impact factor: 7.561

6.  Synthesis and Biological Evaluation of a Novel C8-Pyrrolobenzodiazepine (PBD) Adenosine Conjugate. A Study on the Role of the PBD Ring in the Biological Activity of PBD-Conjugates.

Authors:  Lindsay Ferguson; Sanjib Bhakta; Keith R Fox; Geoff Wells; Federico Brucoli
Journal:  Molecules       Date:  2020-03-10       Impact factor: 4.411

7.  Characterization of the MurT/GatD complex in Mycobacterium tuberculosis towards validating a novel anti-tubercular drug target.

Authors:  Arundhati Maitra; Syamasundari Nukala; Rachael Dickman; Liam T Martin; Tulika Munshi; Antima Gupta; Adrian J Shepherd; Kristine B Arnvig; Alethea B Tabor; Nicholas H Keep; Sanjib Bhakta
Journal:  JAC Antimicrob Resist       Date:  2021-03-16

8.  Analogues of Disulfides from Allium stipitatum Demonstrate Potent Anti-tubercular Activities through Drug Efflux Pump and Biofilm Inhibition.

Authors:  Cynthia A Danquah; Eleftheria Kakagianni; Proma Khondkar; Arundhati Maitra; Mukhlesur Rahman; Dimitrios Evangelopoulos; Timothy D McHugh; Paul Stapleton; John Malkinson; Sanjib Bhakta; Simon Gibbons
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

9.  Nano-Formulation of Ethambutol with Multifunctional Graphene Oxide and Magnetic Nanoparticles Retains Its Anti-Tubercular Activity with Prospects of Improving Chemotherapeutic Efficacy.

Authors:  Bullo Saifullah; Arundhati Maitra; Alina Chrzastek; Bullo Naeemullah; Sharida Fakurazi; Sanjib Bhakta; Mohd Zobir Hussein
Journal:  Molecules       Date:  2017-10-12       Impact factor: 4.411

10.  Novel Anti-Tuberculosis Nanodelivery Formulation of Ethambutol with Graphene Oxide.

Authors:  Bullo Saifullah; Alina Chrzastek; Arundhati Maitra; Bullo Naeemullah; Sharida Fakurazi; Sanjib Bhakta; Mohd Zobir Hussein
Journal:  Molecules       Date:  2017-10-12       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.